These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31574181)

  • 1. Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days.
    Infanti L; Holbro A; Passweg J; Bolliger D; Tsakiris DA; Merki R; Plattner A; Tappe D; Irsch J; Lin JS; Corash L; Benjamin RJ; Buser A
    Transfusion; 2019 Nov; 59(11):3350-3361. PubMed ID: 31574181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre.
    Amato M; Schennach H; Astl M; Chen CY; Lin JS; Benjamin RJ; Nussbaumer W
    Vox Sang; 2017 Jan; 112(1):47-55. PubMed ID: 28001297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient outcomes and amotosalen/UVA-treated platelet utilization in massively transfused patients.
    Nussbaumer W; Amato M; Schennach H; Astl M; Chen CY; Lin JS; Corash L; Benjamin RJ
    Vox Sang; 2017 Apr; 112(3):249-256. PubMed ID: 28198023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
    Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
    Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of amotosalen and UVA pathogen-reduced apheresis platelets after 7-day storage.
    Cancelas JA; Genthe JR; Stolla M; Rugg N; Bailey SL; Nestheide S; Shaz B; Mack S; Schroeder K; Anani W; Szczepiorkowski ZM; Dumont LJ; Yegneswaran S; Corash L; Mufti N; Benjamin RJ; Erickson AC
    Transfusion; 2022 Aug; 62(8):1619-1629. PubMed ID: 35808974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfusion of pathogen-reduced platelet components without leukoreduction.
    Sim J; Tsoi WC; Lee CK; Leung R; Lam CCK; Koontz C; Liu AY; Huang N; Benjamin RJ; Vermeij HJ; Stassinopoulos A; Corash L; Lie AKW
    Transfusion; 2019 Jun; 59(6):1953-1961. PubMed ID: 30919465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components.
    Sigle JP; Infanti L; Studt JD; Martinez M; Stern M; Gratwohl A; Passweg J; Tichelli A; Buser AS
    Transfusion; 2013 Aug; 53(8):1788-97. PubMed ID: 23176347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypersensitivity transfusion reactions to platelet concentrate: a retrospective analysis of the French hemovigilance network.
    Mertes PM; Tacquard C; Andreu G; Kientz D; Gross S; Malard L; Drouet C; Carlier M; Gachet C; Sandid I; Boudjedir K
    Transfusion; 2020 Mar; 60(3):507-512. PubMed ID: 30907010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events.
    Hamzeh-Cognasse H; Laradi S; Osselaer JC; Cognasse F; Garraud O
    Vox Sang; 2015 Feb; 108(2):205-7. PubMed ID: 25334045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage.
    Pitman JP; Payrat JM; Park MS; Liu K; Corash L; Benjamin RJ
    Transfusion; 2023 Apr; 63(4):711-723. PubMed ID: 36802055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
    Knutson F; Osselaer J; Pierelli L; Lozano M; Cid J; Tardivel R; Garraud O; Hervig T; Domanovic D; Cukjati M; Gudmundson S; Hjalmarsdottir IB; Castrillo A; Gonzalez R; Brihante D; Santos M; Schlenke P; Elliott A; Lin JS; Tappe D; Stassinopoulos A; Green J; Corash L
    Vox Sang; 2015 Nov; 109(4):343-52. PubMed ID: 25981525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of amotosalen plus ultraviolet A-mediated pathogen reduction for all platelet concentrates in France: Impact on the risk of transfusion-transmitted infections.
    Richard P; Pouchol E; Sandid I; Aoustin L; Lefort C; Chartois AG; Baima A; Malard L; Bacquet C; Ferrera-Tourenc V; Gallian P; Laperche S; Bliem C; Morel P; Tiberghien P
    Vox Sang; 2024 Mar; 119(3):212-218. PubMed ID: 38152857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions.
    Arnason NA; Johannson F; Landrö R; Hardarsson B; Irsch J; Gudmundsson S; Rolfsson O; Sigurjonsson OE
    Transfusion; 2019 Dec; 59(12):3727-3735. PubMed ID: 31674051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogen-reduced platelets for the prevention of bleeding.
    Butler C; Doree C; Estcourt LJ; Trivella M; Hopewell S; Brunskill SJ; Stanworth S; Murphy MF
    Cochrane Database Syst Rev; 2013 Mar; (3):CD009072. PubMed ID: 23543569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation--a LC-ESI-MS/MS-based proteomics approach.
    Thiele T; Sablewski A; Iuga C; Bakchoul T; Bente A; Görg S; Völker U; Greinacher A; Steil L
    Blood Transfus; 2012 May; 10 Suppl 2(Suppl 2):s63-70. PubMed ID: 22890270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use.
    Osselaer JC; Doyen C; Defoin L; Debry C; Goffaux M; Messe N; Van Hooydonk M; Bosly A; Lin JS; Lin L; Corash L
    Transfusion; 2009 Jul; 49(7):1412-22. PubMed ID: 19389022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of transfusion-associated graft-versus-host disease with pathogen-reduced platelets with amotosalen and ultraviolet A light: a review.
    Cid J
    Vox Sang; 2017 Oct; 112(7):607-613. PubMed ID: 28833219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of platelet concentrates suspended in bicarbonated Ringer's solution in children who had platelet transfusion reactions.
    Kobayashi J; Yanagisawa R; Ono T; Tatsuzawa Y; Tokutake Y; Kubota N; Hidaka E; Sakashita K; Kojima S; Shimodaira S; Nakamura T
    Vox Sang; 2018 Feb; 113(2):128-135. PubMed ID: 29067694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inactivation of yellow fever virus with amotosalen and ultraviolet A light pathogen-reduction technology.
    Girard YA; Santa Maria F; Lanteri MC
    Transfusion; 2020 Mar; 60(3):622-627. PubMed ID: 31957887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Conventional vs pathogen-inactivated platelet concentrates for the treatment of perioperative coagulopathy. A prospective cohort study].
    Weber CF; Meininger D; Byhahn C; Seifried E; Zacharowski K; Adam E; Henschler R; Müller MM
    Chirurg; 2011 Apr; 82(4):348-58. PubMed ID: 21249326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.